- cafead   Apr 02, 2020 at 10:52: AM
via Citius Pharmaceuticals has entered into an exclusive six-month option agreement with Novellus subsidiary to licence novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19, the disease caused due to the novel coronavirus SARS-CoV-2.
article source
article source